MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
6.12
-0.21
-3.32%
Opening 15:00 12/17 EST
OPEN
6.77
PREV CLOSE
6.33
HIGH
6.77
LOW
6.05
VOLUME
86.74K
TURNOVER
--
52 WEEK HIGH
12.45
52 WEEK LOW
3.510
MARKET CAP
104.35M
P/E (TTM)
-0.4198
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanks · 14h ago
Weekly Report: what happened at KPTI last week (1208-1212)?
Weekly Report · 2d ago
Karyopharm Therapeutics Joins Baird's Biotech Discovery Series Fireside Chat
Reuters · 12/08 12:01
Karyopharm to Participate in Baird's Biotech Discovery Series
PR Newswire · 12/08 12:00
Weekly Report: what happened at KPTI last week (1201-1205)?
Weekly Report · 12/08 09:25
Karyopharm Therapeutics Grants Stock Options and RSUs to New Employees
Reuters · 12/01 21:05
KARYOPHARM THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/01 21:05
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 12/01 21:05
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.